

Resource Summary Report

Generated by RRID on Aug 4, 2026

CalcuSyn

RRID:SCR_020251

Type: Tool

Proper Citation

CalcuSyn (RRID:SCR_020251)

Resource Information

URL: <http://www.biosoft.com/w/calculusyn.htm>

Proper Citation: CalcuSyn (RRID:SCR_020251)

Description: Software tool for drug mixtures study and establishing efficacy. Dose effect analyzer of combined drugs. Able to quantify synergism and inhibition. CalcuSyn Version 2.0 has Undo and Redo tools.

Synonyms: CalcuSyn Version 2.0

Resource Type: software resource, data processing software, software application, data analysis software

Keywords: Biosoft, drug mixtures study, drug efficacy, dose effect, quantify synergism, quantify inhibition

Availability: Restricted

Resource Name: CalcuSyn

Resource ID: SCR_020251

Record Creation Time: 20220129T080349+0000

Record Last Update: 20260804T043729+0000

Ratings and Alerts

No rating or validation information has been found for CalcuSyn.

No alerts have been found for CalcuSyn.

Data and Source Information

Usage and Citation Metrics

We found 57 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Spender LC, et al. (2025) AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma. *British journal of cancer*, 133(5), 709.

Keser M, et al. (2025) Design, Synthesis, and Molecular Docking of Triazole-Coumarin Hybrids as Potent Breast Cancer Inhibitors Targeting Cell Cycle and Apoptosis. *Chemistry & biodiversity*, 22(12), e01775.

Meric-Bernstam F, et al. (2025) Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(3), 573.

Oh S, et al. (2025) The Synergistic Effect of PARP Inhibitors and Irinotecan in Small Cell Lung Cancer Cells. *Cancer research and treatment*, 57(4), 1040.

Anastasio G, et al. (2025) Enhancing PDAC therapy: Decitabine-olaparib synergy targets KRAS-dependent tumors. *iScience*, 28(2), 111842.

Araújo NM, et al. (2025) The antitumor effect of tlr4 inhibition in head and neck cancer cell lines. *Scientific reports*, 15(1), 31681.

Xing HB, et al. (2025) Resveratrol synergizes with cisplatin to suppress osteosarcoma U2-OS cells via up-regulating Cx43 and inducing ROS-dependent apoptosis. *Discover oncology*, 16(1), 2218.

Massa A, et al. (2025) Doxycycline Restores Gemcitabine Sensitivity in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. *Cancers*, 17(1).

Melcón-Fernández E, et al. (2024) In Vitro and Ex Vivo Synergistic Effect of Pyrvinium Pamoate Combined with Miltefosine and Paromomycin against Leishmania. *Tropical medicine and infectious disease*, 9(2).

Chen SY, et al. (2024) Advancing Lung Cancer Treatment with Combined c-Met Promoter-Driven Oncolytic Adenovirus and Rapamycin. *Cells*, 13(18).

Bojkova D, et al. (2023) Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform. *iScience*, 26(2), 105944.

Li Y, et al. (2023) Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. *Journal of experimental & clinical cancer research : CR*, 42(1), 6.

Yang Z, et al. (2023) A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantation. *EBioMedicine*, 92, 104594.

Lee CL, et al. (2023) Preclinical evaluation of the CDK4/6 inhibitor palbociclib in combination with a PI3K or MEK inhibitor in colorectal cancer. *Cancer biology & therapy*, 24(1), 2223388.

DiPeri TP, et al. (2023) Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(21), 4385.

Vanaroj P, et al. (2023) Atractylodin and β -eudesmol from *Atractylodes lancea* (Thunb.) DC. Inhibit Cholangiocarcinoma Cell Proliferation by Downregulating the Notch Signaling Pathway. *Asian Pacific journal of cancer prevention : APJCP*, 24(2), 551.

Centonze G, et al. (2023) p140Cap modulates the mevalonate pathway decreasing cell migration and enhancing drug sensitivity in breast cancer cells. *Cell death & disease*, 14(12), 849.

Melcon-Fernandez E, et al. (2023) Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of *Leishmania donovani* Visceral Leishmaniasis. *International journal of molecular sciences*, 24(2).

Wang X, et al. (2022) PSMG2-controlled proteasome-autophagy balance mediates the tolerance for MEK-targeted therapy in triple-negative breast cancer. *Cell reports. Medicine*, 3(9), 100741.

Rong X, et al. (2022) Close association between the synergistic toxicity of zearalenone-deoxynivalenol combination and microRNA221-mediated PTEN/PI3K/AKT signaling in HepG2 cells. *Toxicology*, 468, 153104.